Skip to main content
GutCited

Alpha-Galactosidase Irritable Bowel Syndrome (IBS)

D

Single study in IBS patients consuming high-FODMAP diet. May reduce gas-related symptoms from specific food triggers.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dalpha\u002Dgalactosidase\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

結論

Single study in IBS patients consuming high-FODMAP diet. May reduce gas-related symptoms from specific food triggers.

Key Study Findings

Review
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.
Dose: None vs: None Outcome: None 効果: None None

対象集団: None

Randomized Controlled Trial Double-blind
A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal …
Dose: 1200 G vs: placebo Outcome: every 30 min during 7 効果: None None

対象集団: patients with ibs after three standardized

Randomized Controlled Trial n=31 2.0 weeks Double-blind
Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.
Dose: 300 GALU or 150 GALU vs: Placebo (glucose) Outcome: GI symptom severity on VAS 効果: None pP0.006

対象集団: IBS patients (Rome III, H2 producers)

Randomized Controlled Trial n=125 4 weeks Double-blind
Does oral α-galactosidase relieve irritable bowel symptoms?
Dose: alpha-galactosidase 600 GalU per meal vs: placebo Outcome: overall IBS symptom relief 効果: no significant difference vs placebo >0.05

対象集団: IBS patients

Key Statistics

1

研究数

60

参加者数

Positive

D

グレード

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods
standardbeanodose:
300 GalU (2-3 tablets) with first bite of problem food

上限量: No established upper limit; adjust per meal as needed

研究で検討された用量

用量 期間 効果 N
None -- Mixed --
1200 G -- Neutral --
300 GALU or 150 GALU 2.0 weeks Positive 31
alpha-galactosidase 600 GalU per meal 4 weeks Neutral 125

推奨摂取タイミング: With the first bite of gas-producing food

Safety & Side Effects

報告されている副作用

  • Generally very well-tolerated
  • Rare allergic reactions to mold-derived enzyme (Aspergillus source)
  • May cause mild GI discomfort in rare cases

既知の相互作用

  • Acarbose (alpha-galactosidase may counteract the blood sugar-lowering mechanism of acarbose; contraindicated for concurrent use)
  • Miglitol (similar mechanism conflict as acarbose)

耐容上限摂取量: No established upper limit; adjust per meal as needed

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Alpha-Galactosidase help with Irritable Bowel Syndrome (IBS)?
Based on 1 studies with 60 participants, there is preliminary evidence that needs more research that Alpha-Galactosidase may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Alpha-Galactosidase should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Alpha-Galactosidase?
Reported side effects may include Generally very well-tolerated, Rare allergic reactions to mold-derived enzyme (Aspergillus source), May cause mild GI discomfort in rare cases. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Alpha-Galactosidase and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 1 peer-reviewed studies with 60 total participants. The overall direction of effect is positive.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。